DAVITA INC. Segment Expenditure Addition To Long Lived Assets
DAVITA INC. (DVA) reported Segment Expenditure Addition To Long Lived Assets of $271.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentExpenditureAdditionToLongLivedAssets · last filed 2026-08-04
- DAVITA INC. segment expenditure addition to long lived assets for the quarter ending 2026-06-30 was $169.82M, a 40.24% increase year-over-year.
- DAVITA INC. segment expenditure addition to long lived assets for the quarter ending 2026-03-31 was $102.02M, a 28.79% decline year-over-year.
- DAVITA INC. segment expenditure addition to long lived assets for the quarter ending 2025-12-31 was $145.43M, a 14.78% decline year-over-year.
- DAVITA INC. segment expenditure addition to long lived assets for the quarter ending 2025-09-30 was $166.09M, a 19.45% increase year-over-year.
- DAVITA INC. segment expenditure addition to long lived assets for fiscal 2025 was $575.86M, a 3.68% increase from fiscal 2024.
- DAVITA INC. segment expenditure addition to long lived assets for fiscal 2024 was $555.44M, a 2.21% decline from fiscal 2023.
- DAVITA INC. segment expenditure addition to long lived assets for fiscal 2023 was $567.99M, a 5.87% decline from fiscal 2022.
- DAVITA INC. segment expenditure addition to long lived assets for fiscal 2022 was $603.43M, a 5.93% decline from fiscal 2021.
| Period end | Segment Expenditure Addition To Long Lived Assets 3 month | Segment Expenditure Addition To Long Lived Assets 6 month | Segment Expenditure Addition To Long Lived Assets 9 month | Segment Expenditure Addition To Long Lived Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $169.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $271.84M 10-Q · filed 2026-08-04 | $417.27M derived: sum of 3 quarters · filed 2026-08-04 | $583.35M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $102.02M 10-Q · filed 2026-05-05 | $247.45M derived: sum of 2 quarters · filed 2026-05-05 | $413.53M derived: sum of 3 quarters · filed 2026-05-05 | $534.62M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $145.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $311.51M derived: sum of 2 quarters · filed 2026-02-11 | $432.61M derived: sum of 3 quarters · filed 2026-08-04 | $575.86M 10-K · filed 2026-02-11 |
| 2025-09-30 | $166.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $287.18M derived: sum of 2 quarters · filed 2026-08-04 | $430.43M 10-Q · filed 2025-10-29 | $601.09M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $121.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $264.35M 10-Q · filed 2026-08-04 | $435.01M derived: sum of 3 quarters · filed 2026-08-04 | $574.05M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $143.26M 10-Q · filed 2026-05-05 | $313.92M derived: sum of 2 quarters · filed 2026-05-05 | $452.96M derived: sum of 3 quarters · filed 2026-05-05 | $577.69M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $170.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $309.70M derived: sum of 2 quarters · filed 2026-02-11 | $434.43M derived: sum of 3 quarters · filed 2026-02-11 | $555.44M 10-K · filed 2026-02-11 |
| 2024-09-30 | $139.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $263.77M derived: sum of 2 quarters · filed 2025-10-29 | $384.79M 10-Q · filed 2025-10-29 | $543.76M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $124.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $245.74M 10-Q · filed 2025-08-05 | $404.71M derived: sum of 3 quarters · filed 2026-02-11 | $541.52M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $121.02M 10-Q · filed 2025-05-12 | $279.99M derived: sum of 2 quarters · filed 2026-02-11 | $416.80M derived: sum of 3 quarters · filed 2026-02-11 | $541.29M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $158.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $295.78M derived: sum of 2 quarters · filed 2026-02-11 | $420.28M derived: sum of 3 quarters · filed 2026-02-11 | $567.99M 10-K · filed 2026-02-11 |
| 2023-09-30 | $136.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $261.31M derived: sum of 2 quarters · filed 2024-10-29 | $409.01M 10-Q · filed 2024-10-29 | |
| 2023-06-30 | $124.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $272.20M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $147.71M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $603.43M 10-K · filed 2025-02-13 | |||
| 2021-12-31 | $641.47M 10-K · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |